A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway

por Kim, Dong Seok, Choi, Ho-Il, Wang, Yun, Luo, Yu, Hoffer, Barry J., Greig, Nigel H.
Publicado 2017

Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon

por Li, Yazhou, Vaughan, Kelli L., Tweedie, David, Jung, Jin, Kim, Hee Kyung, Choi, Ho-Il, Kim, Dong Seok, Mattison, Julie A., Greig, Nigel H.
Publicado 2019

Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease

por Chen, Shuchun, Yu, Seong-Jin, Li, Yazhou, Lecca, Daniela, Glotfelty, Elliot, Kim, Hee Kyung, Choi, Ho-Il, Hoffer, Barry J., Greig, Nigel H., Kim, Dong Seok, Wang, Yun
Publicado 2018

Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Park...

por Chen, Shuchun, Yu, Seong-Jin, Li, Yazhou, Lecca, Daniela, Glotfelty, Elliot, Kim, Hee Kyung, Choi, Ho-Il, Hoffer, Barry J., Greig, Nigel H., Kim, Dong Seok, Wang, Yun
Publicado 2018

PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease

por Yu, Seong-Jin, Chen, Shuchun, Yang, Yung-Yung, Glotfelty, Elliot J., Jung, Jin, Kim, Hee Kyung, Choi, Ho-Il, Choi, Doo-Sup, Hoffer, Barry J., Greig, Nigel H., Wang, Yun
Publicado 2020